1092499-93-8

Basic information

• Product Name: NVP-BSK805
• Synonyms: NVP-BSK805;NVP-BSK805 dihydrochloride;8-[3,5-Difluoro-4-(4-morpholinylmethyl)phenyl]-2-[1-(4-piperidinyl)-1H-pyrazol-4-yl]quinoxaline;NVP-BSK805 2HCl;BSK 805;BSK805;BSK-805;8-(3,5-difluoro-4-(morpholinomethyl)phenyl)-2-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxaline
• CAS NO: 1092499-93-8
• Molecular Formula: C₂₇H₂₈F₂N₆O
• Molecular Weight: 490.5476264
• Product Categories: Inhibitor;Inhibitors;JAK;STAT
• Mol File: 1092499-93-8.mol
• Article Data: 2

Chemical Properties

• Melting Point: 137℃
• Appearance: /
• Density: 1.4
• Solubility: ≥20.95 mg/mL in DMSO; ≥3.45 mg/mL in H2O with gentle warming and ultrasonic; ≥4.75 mg/mL in EtOH with gentle warming and ultrasonic
• CAS DataBase Reference: NVP-BSK805(CAS DataBase Reference)
• NIST Chemistry Reference: NVP-BSK805(1092499-93-8)
• EPA Substance Registry System: NVP-BSK805(1092499-93-8)

Safety Data

• Hazardous Substances Data: 1092499-93-8(Hazardous Substances Data)

Usage

General Description

NVP-BSK805 is a potent, selective, and orally bioavailable ATP-competitive JAK2 inhibitor. Its full name is 5-(4-(8-Fluoro-5-(quinolin-5-yl)-2,3,5,7-tetrahydro-[1,4]dioxepino[2,3-g]quinolin-1-yl)phenyl)isoxazole-3-carboxamide. This chemical is associated with treating inflammatory conditions, immunological conditions, and cancer-related conditions, due to its potential to inhibit the overactive JAK2 protein which plays a significant role in these diseases. The inhibitor demonstrates activity against multiple myeloma, leukemia, and lymphoma cells. It is notable for its advantageous pharmacokinetic characteristics and good safety profile.

Upstream product

• 1092500-75-8 8-bromo-2-(1-piperidin-4-yl-1H-pyrazol-4-yl)-quinoxaline 

Downstream Products

• 1092500-23-6 cyclopropyl-(4-{4-[8-(3,5-difluoro-4-morpholin-4-ylmethyl-phenyl)-quinoxalin-2-yl]-pyrazol-1-yl}-piperidin-1-yl)-methanone 
• 1092500-17-8 8-(3,5-difluoro-4-morpholin-4-ylmethyl-phenyl)-2-{1-[1-(2-methoxy-ethyl)-piperidin-4-yl]-1H-pyrazol-4-yl}-quinoxaline 
• 1092500-16-7 4-{4-[8-(3,5-difluoro-4-morpholin-4-ylmethyl-phenyl)-quinoxalin-2-yl]-pyrazol-1-yl}-piperidine-1-carboxylic acid 2-methoxy-ethyl ester 
• 1092500-24-7 4-{4-[8-(3,5-difluoro-4-morpholin-4-ylmethyl-phenyl)-quinoxalin-2-yl]-pyrazol-1-yl}-piperidine-1-carboxylic acid methyl ester 

Relevant articles and documents

Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors

We have designed and synthesized a novel series of 2,8-diaryl-quinoxalines as Janus kinase 2 inhibitors. Many of the inhibitors show low nanomolar activity against JAK2 and potently suppress proliferation of SET-2 cells in vitro. In addition, compounds from this series have favorable rat pharmacokinetic properties suitable for in vivo efficacy evaluation.